Home LiteratureArticle Details
PMID: 87679 Published · ppublish English Journal Article

Improvement of chronic congestive heart-failure by oral captopril.

Lancet (London, England) ·Vol. 1 ·No. 8128 ·1979-06-09 ·Pages 1213-5

Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H

Abstract

Catopril, an inhibitor of angiotensin converting enzyme, was given orally during cardiac catheterisation to 6 normotensive patients with refractory congestive heart-failure. 60--180 minutes after administration of 25 mg captopril, arterial pressure fell by 25%, cardiac index rose by 38%, and left-ventricular pressure and right-atrial pressure fell by 25% and 40% respectively. Plasma-renin activity rose while plasma noradrenaline and aldosterone fell. These data suggest that, in the short term, captopril can reduce both preload and afterload, and improve cardiac function, in refractory congestive heart-failure.

MeSH Terms
Administration, Oral Adult Angiotensin-Converting Enzyme Inhibitors Blood Pressure/drug effects Cardiac Output/drug effects Chronic Disease Drug Evaluation Heart Failure/drug therapy,physiopathology Humans Male Middle Aged Mineralocorticoid Receptor Antagonists Norepinephrine/antagonists & inhibitors Proline/administration & dosage,analogs & derivatives Renin/blood Vascular Resistance/drug effects
Chemicals
Angiotensin-Converting Enzyme Inhibitors Mineralocorticoid Receptor Antagonists Proline Renin Norepinephrine
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Turini G A
Brunner H R
Gribic M
Waeber B
Gavras H
Article Info
Journal
Lancet (London, England)
Abbr.
Lancet
ISSN
0140-6736
Published
1979-06-09
Pages
1213-5
Language
English
Region
England
NLM ID
2985213R
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com